2-(2-Alkoxy-5-heterocyclylsulphonylphenyl)purin-6-ones as phosphodiesterase inhibitors
申请人:Pfizer Limited
公开号:EP1092718A1
公开(公告)日:2001-04-18
There is provided compounds of formula IA and of formula IB,
wherein R1, R2, R3, Het1 and X have meanings given in the description, which are useful in the curative and prophylactic treatment of medical conditions for which inhibition of a cyclic guanosine 3',5'-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
提供了式 IA 和式 IB 的化合物、
其中 R1、R2、R3、Het1 和 X 具有描述中给出的含义,可用于治疗和预防需要抑制环鸟苷-3',5'-单磷酸磷酸二酯酶(如 cGMP PDE5)的病症。
US6440982B1
申请人:——
公开号:US6440982B1
公开(公告)日:2002-08-27
US6586439B2
申请人:——
公开号:US6586439B2
公开(公告)日:2003-07-01
US6593332B2
申请人:——
公开号:US6593332B2
公开(公告)日:2003-07-15
Pharmaceutically active compounds
申请人:Pfizer Inc.
公开号:US06440982B1
公开(公告)日:2002-08-27
There is provided compounds of formula IA and of formula IB,
wherein R1, R2, R3, Het1 and X have meanings given in the description, which are useful in the curative and prophylactic treatment of medical conditions for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.